PROS1 and COVID-19: A recombinant S-protein-based vaccine adjuvanted with ASO3 in the DP has also entered Phase 3 clinical trials, and similar considerations for potency assay apply (https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-3-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate).